AMENDMENTS TO THE SPECIFICATION:

Please amend the paragraphs beginning on page 7, line 10, through page 8, line 2, as follows:

In a first aspect, this invention provides a method of treating amyloidosis in a mammal suffering therefrom, comprising administration to the mammal of a therapeutically effective amount of an isolated pure compound selected from the group consisting of the compounds of formula A, formula B, formula C, formula D, and formula E:



Formula A



Formula B



Formula C



Formula D



Formula E

where:

R is selected from the group consisting of hydrogen, 2,3-dihydroxybenzoyl, 3,4-dihydroxybenzoyl, ~~2,34-trihydroxybenzoyl~~ 2,3,4-trihydroxybenzoyl, and 3,4,5-trihydroxybenzoyl;

Please amend the paragraph on page 10, lines 3-11, as follows:

In a third aspect, this invention provides a method of treating a disease characterized by α-synuclein fibril formation in a mammal suffering therefrom, comprising administration to the mammal of a therapeutically effective amount of an

isolated pure compound selected from the group consisting of the compounds of formula A, formula B, formula C, formula D, and formula E:



Formula A



Formula B



Formula C



Formula D



Formula E

where:

R is selected from the group consisting of hydrogen, 2,3-dihydroxybenzoyl, 3,4-dihydroxybenzoyl, ~~2,34-trihydroxybenzoyl~~ 2,3,4-trihydroxybenzoyl, and 3,4,5-trihydroxybenzoyl;

Please amend the paragraphs beginning on page 16, lines 25-29,as follows:

The therapeutic ratio of a compound can be determined, for example, by comparing the dose that gives effective anti-fibril (anti-amyloid or ~~anti-α-synuclein~~ anti-α-synuclein) activity in a suitable *in vivo* model in a suitable animal species such as the mouse, with the dose that gives significant weight loss (or other observable side-effects) in the test animal species.